<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome is a <z:hpo ids='HP_0011010'>chronic</z:hpo> relapsing <z:hpo ids='HP_0002633'>vasculitis</z:hpo> characterized by aphthous <z:hpo ids='HP_0010280'>stomatitis</z:hpo>, <z:e sem="disease" ids="C0151281" disease_type="Disease or Syndrome" abbrv="">genital ulcerations</z:e>, and <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The disease is a multisystem illness, which may involve the skin, joints, gastrointestinal tract, blood vessels, central <z:mp ids='MP_0008912'>nervous</z:mp> system, and other organs </plain></SENT>
<SENT sid="2" pm="."><plain>CASE STUDY: We report a case of an infant with features of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome who did not respond to conventional immunosuppression with high-dose <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and cytotoxic agents </plain></SENT>
<SENT sid="3" pm="."><plain>Thalidomide, a potent immune response-modifying drug, was used with marked improvement and resolution of symptoms </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: This finding supports a trial of thalidomide treatment in patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome who are unresponsive to other forms of immunosuppressive therapy or develop undesirable side effects </plain></SENT>
</text></document>